Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 15;44(9):1938–1947. doi: 10.2337/dc21-0027

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the American Diabetes Association

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.

PMC Copyright notice

Life table estimate to progression from IGT to type 2 diabetes. A: Cumulative incidence of type 2 diabetes in youth over the duration of the study among youth with IGT at baseline. The progression to type 2 diabetes did not differ in youth between glargine, followed by metformin (G-MET) or metformin alone (MET) at M12 (P = 0.28) or M21 (P = 0.40). B: Cumulative incidence of type 2 diabetes in adults over the duration of the study among adults with IGT at baseline. The progression to type 2 diabetes was borderline significant between the four intervention arms at M12 (P = 0.06 for overall comparison) but not at M21 (P = 0.20 for overall comparison). C: Cumulative incidence of type 2 diabetes in youth and adults randomized to metformin (MET) alone vs. glargine, followed by metformin (G-MET), over the duration of the study, among youth and adults with IGT at baseline. The progression to type 2 diabetes did not differ between youth and adults in either intervention arm.